The future of the global adult vaccine market looks promising with opportunities in the private healthcare firm and government hospital markets. The global adult vaccine market is expected to reach an estimated $24.4 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are growing cases of contagious diseases and supportive government initiatives to spread awareness about the importance of vaccination among population.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the adult vaccine market by
technology (live attenuated, inactivated, subunit, toxoid, conjugate , and
others), vaccine type (monovalent and multivalent), end use (private healthcare
firms and government hospitals), and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will
grow at a faster pace and why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the
emerging trends in this market and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market,
monovalent and multivalent are the major segments of adult vaccine market by
Vaccine type. Lucintel forecasts that multivalent is expected to witness higher
growth over the forecast period due to its broader application to protect
against bacterial and viral illnesses.
Within this market,
private healthcare firm is expected to witness higher growth over the forecast
period.
North America is
expected to witness highest growth over the forecast period due to presence of
strong government support for immunization programs and existence of robust
healthcare infrastructure in the region.
Glaxosmithkline, Merck
& Co, Sanofi, Johnson & Johnson, Serum Institute India, Astrazeneca,
and Novartis are the major suppliers in the adult vaccine market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment